Safety and immunogenicity of two doses of quadrivalent meningococcal conjugate vaccine or one dose of meningococcal group C conjugate vaccine, both administered concomitantly with routine immunization to 12- to 18-month-old children
Francisco Noya, Deirdre McCormack, Donna L Reynolds, Dion Neame, Philipp Oster, Francisco Noya, Deirdre McCormack, Donna L Reynolds, Dion Neame, Philipp Oster
Abstract
Objectives: To describe the immunogenicity and safety of a two-dose series of a quadrivalent meningococcal (serogroups A, C, Y and W) polysaccharide diphtheria toxoid conjugate vaccine (MenACYW-D) administered to toddlers.
Methods: Children were randomly assigned (1:1) at study entry to receive MenACYW-D at 12 and 18 months of age (group 1; n=61) or meningococcal serogroup C conjugate vaccine (MCC) at 12 months of age (group 2; n=62). All received routine childhood immunizations. A, C, Y and W antibody titres were measured in group 1 before and one month after the 18-month MenACYW-D vaccination and were measured in group 2 at one and seven months post-MCC vaccination. Antibodies elicited by diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine and Haemophilus influenzae b conjugate (DTaP-IPV-Hib) vaccine coadministered at the 18-month vaccination were measured one month later. Safety data were collected.
Results: At 19 months of age, ≥96% in group 1 achieved protective titres for the four meningococcal serogroups after dose 2; 67% in group 2 exhibited protective titres against serogroup C 28 days after MCC vaccination at 12 months of age, declining to 27% seven months later. DTaP-IPV-Hib elicited high antibody concentrations/titres in groups 1 and 2, consistent with historical values. The safety profiles after each dose generated no unexpected safety signals; no serious adverse events were related to vaccination.
Discussion: A two-dose series of MenACYW-D given concomitantly with a DTaP-IPV-Hib booster dose at 18 months of age demonstrated a good immunogenicity and safety profile. A two-dose series of MenACYW-D can be used as an alternative to one dose of MCC and provides protection against additional serogroups (NCT ID: NCT01359449).
Keywords: Canada; Conjugate; Meningococcal; Quadrivalent; Vaccine.
Figures
References
- Manchanda V, Gupta S, Bhalla P. Meningococcal disease: History, epidemiology, pathogenesis, clinical manifestations, diagnosis, antimicrobial susceptibility and prevention. Indian J Med Microbiol. 2006;24:7–19.
- Harrison OB, Claus H, Jiang Y, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013;19:566–73.
- Pelton SI, Gilmet GP. Expanding prevention of invasive meningococcal disease. Expert Rev Vaccines. 2009;8:717–27.
- Kirsch EA, Barton RP, Kitchen L, Giroir BP. Pathophysiology, treatment and outcome of meningococcemia: A review and recent experience. Pediatr Infect Dis J. 1996;15:967–78. quiz 79.
- Centers for Disease Control and Prevention (CDC) Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2005;54(RR-7):1–21.
- Granoff DM, Pelton S, Harrison D. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th edn. Philadelphia: Saunders Elsevier; 2012. pp. 388–418.
- Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–63.
- Health Canada Web Site. Drugs and Health Products: Bexsero. 2014. < > (Accessed February 26, 2014)
- National Advisory Committee on Immunization (NACI) An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS) Can Commun Dis Rep. 2009;35(ACS-3):1–40.
- Public Health Agency of Canada (PHAC) Invasive meningococcal disease (IMD) 2012. < > (Accessed July 2, 2013)
- Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: Estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis. 2003;36:679–83.
- Public Health Agency of Canada (PHAC) Publicly funded immunization programs in Canada – routine schedule for infants and children including special programs and catch-up programs (as of March 2013) 2013. < > (Accessed July 2, 2013)
- U.S. National Institutes of Health. Study of two doses of Menactra® or one dose of monovalent meningococcal group C vaccine with routine immunizations. 2013. < > (Accessed July 2, 2013)
- Pina LM, Bassily E, Machmer A, Hou V, Reinhardt A. Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: Three multicenter phase III studies. Pediatr Infect Dis J. 2012;31:1173–83.
- Grimprel E, Wysocki J, Boisnard F, Thomas S, Mwawasi G, Reynolds D. Immunogenicity and safety of fully liquid DTaP(5)-IPV-Hib compared with DTaP(3)-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, 4, and 12 to 18 months of age: A phase III, single-blind, randomised, controlled, multicentre study. Vaccine. 2011;29:7370–8.
- Keyserling HL, Pina M, Hou V, Bassily E, DeTora L, Reinhardt A. Immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine against serogroups A, C, Y, and W-135 (MCV-4) in 9- to 15-month olds. Abstract 640. 44th Annual Meeting of the Infectious Disease Society of America (IDSA); Toronto, Ontario. October 12 to 15, 2006.
Source: PubMed